BIOLARGO, INC.
Close on Oct 19, 2026
- Market cap
- $23.27M
- P/E (TTM)
- –
- Dividend yield
- –
About Biolargo
Chemicals & Allied Products, SIC 2800
BioLargo, Inc. invents, develops, and commercializes clean technologies addressing environmental and healthcare challenges. The company operates through distinct business units focused on air quality, water remediation, energy storage, professional engineering, and medical solutions. Its offerings include CupriDyne Clean odor and volatile organic compound control products, the Aqueous Electrostatic Concentrator for removing per- and polyfluoroalkyl substances, and the ViaCLYR wound management solution. Additionally, the company develops liquid sodium battery storage systems and provides multidisciplinary environmental engineering services. BioLargo serves municipalities, solid waste facilities, industrial clients, healthcare distributors, and governmental entities such as the United States Air Force.
The company is headquartered in Westminster, California. Its operations span facilities across the United States and Canada, including an engineering office and battery production facility in Oak Ridge, Tennessee, a healthcare products office in Tampa, Florida, and a research facility located at the University of Alberta in Edmonton, Alberta, Canada. As of March 2026, the company employed 46 individuals, including 44 full-time staff members.
Summary of the business section of Biolargo's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BIOLARGO, INC.
- Headquarters
- Westminster, CA
- Address
- 14921 Chestnut St. 92683
- Phone
- (888) 400-2863
- Website
- biolargo.com
- Employees
- 46, Dec 31, 2025
- Industry
- Chemicals & Allied Products
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- HACKER JOHNSON & SMITH PA, Tampa, Florida
Stock & identifiers
- Ticker
- BLGO
- Exchange
- OTC
- Shares outstanding
- 329M, Aug 12, 2026
- Public float
- $63.07M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 880242
- CUSIP
- 09065A100
- ISIN
- US09065A1007
- LEI
- 5493007RC0EO4XEQU443
- EIN
- 65-0159115
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kenneth Reay Code | Chief Science Officer, Director | 48,547,331 |
| Dennis P. Calvert | President, Director | 12,586,803 |
| Charles K. Dargan | Chief Financial Officer | 190,244 |
| Dennis E. Marshall | Director | 414,737 |
| Linda Park | Director | 190,362 |
| Jack B. Strommen | Director | 9,194,123 |
| Christina Elaine Bray | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 | $317.95K | $317.95K | $265.50K | $90 | – |
| FY2023 | $316.59K | $299.40K | $214.93K | $79 | – |
| FY2022 | $455.97K | $313.56K | $226.51K | $92 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 2, 2026, we had 46 employees, of which 44 were full-time.”
Corporate history
Events identified from SEC filings